- Home
- BMM vs CERS Comparison
BMM vs CERS Comparison
Compare BMM & CERS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | BMM | CERS |
|---|---|---|
| Founded | 2007 | 1991 |
| Country | Canada | United States |
| Employees | 27 | N/A |
| Industry | | EDP Services |
| Sector | | Technology |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 316.1M | 276.0M |
| IPO Year | N/A | 1996 |
Fundamental Metrics
Financial Performance| Metric | BMM | CERS |
|---|---|---|
| Price | $5.76 | $1.78 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 104.6K | ★ 2.2M |
| Earning Date | 02-27-2026 | 03-02-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 27.27 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $51,326,000.00 |
| Revenue This Year | N/A | $19.95 |
| Revenue Next Year | N/A | $8.84 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 30.68 |
| 52 Week Low | $3.47 | $1.12 |
| 52 Week High | $6.56 | $2.96 |
Technical Indicators
Market Signals| Indicator | BMM | CERS |
|---|---|---|
| Relative Strength Index (RSI) | 57.89 | 39.36 |
| Support Level | $4.79 | $1.49 |
| Resistance Level | $5.97 | $1.78 |
| Average True Range (ATR) | 0.43 | 0.11 |
| MACD | -0.05 | 0.01 |
| Stochastic Oscillator | 56.97 | 45.31 |
Price Performance
Historical ComparisonAbout BMM Blue Moon Metals Inc. Common Shares
Blue Moon Metals Inc is a Canadian exploration stage company which is focused on the exploration and development of mineral resource properties. The company is advancing its Blue Moon polymetallic deposit which contains zinc, gold, silver, and copper. The company also holds the Yava polymetallic project in Nunavut that is in the same volcanic lithologies and south of Glencore's Hackett River deposit. The company is focusing on advancing the Blue Moon and Yava properties.
About CERS Cerus Corporation
Cerus Corp is a biomedical products company focused on the field of blood transfusion safety. The INTERCEPT Blood System is designed to reduce the risk of transfusion-transmitted infections by inactivating a broad range of pathogens such as viruses, bacteria, and parasites. The company sells its INTERCEPT platelet and plasma systems in the United States of America, Europe, the Commonwealth of Independent States countries, the Middle East, and selected countries in other regions around the world. The firm continues to operate in only one segment: Blood safety and generates revenue from the same.